Profile data is unavailable for this security.
About the company
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
- Revenue in USD (TTM)0.00
- Net income in USD-29.69m
- Incorporated2009
- Employees10.00
- LocationAtossa Therapeutics Inc107 Spring StSEATTLE 98104-1005United StatesUSA
- Phone+1 (206) 588-0256
- Fax+1 (302) 636-5454
- Websitehttps://atossatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CytoDyn Inc | 0.00 | -51.69m | 193.71m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Galectin Therapeutics Inc | 0.00 | -44.78m | 195.62m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| bluebird bio Inc | 21.73m | -91.17m | 196.07m | 323.00 | -- | 0.4954 | -- | 9.02 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
| Zevra Therapeutics Inc | 28.01m | -50.90m | 196.29m | 65.00 | -- | 4.02 | -- | 7.01 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4929 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 196.38m | 75.00 | -- | 2.71 | -- | 24.54 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Trevi Therapeutics Inc | 0.00 | -33.57m | 199.33m | 25.00 | -- | 2.70 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 199.72m | 36.00 | 199.89 | 65.74 | 70.23 | 4.44 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 200.41m | 101.00 | -- | 10.80 | -- | 7.40 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Atossa Therapeutics Inc | 0.00 | -29.69m | 201.21m | 10.00 | -- | 2.34 | -- | -- | -0.2359 | -0.2359 | 0.00 | 0.6833 | 0.00 | -- | -- | 0.00 | -28.65 | -29.97 | -29.84 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 204.35m | 29.00 | -- | 2.55 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 207.72m | 46.00 | -- | 1.76 | -- | 12.81 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Veru Inc | 13.48m | -35.82m | 207.87m | 189.00 | -- | 4.60 | -- | 15.42 | -0.3465 | -0.3465 | 0.1267 | 0.3089 | 0.1898 | 1.42 | 3.86 | 71,318.68 | -50.43 | -42.91 | -76.84 | -54.41 | 34.13 | 72.41 | -265.74 | -104.96 | 4.22 | -- | 0.177 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| AVITA Medical Inc | 50.70m | -44.82m | 210.78m | 207.00 | -- | 6.47 | -- | 4.16 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Puma Biotechnology Inc | 226.63m | 15.38m | 210.80m | 185.00 | 13.58 | 4.13 | 7.83 | 0.9302 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Data as of May 20 2024. Currency figures normalised to Atossa Therapeutics Inc's reporting currency: US Dollar USD
12.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.71m | 4.56% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.30m | 1.84% |
| Laurion Capital Management LPas of 31 Mar 2024 | 2.23m | 1.78% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.39m | 1.11% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.21m | 0.97% |
| Millennium Management LLCas of 31 Mar 2024 | 1.01m | 0.81% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 739.81k | 0.59% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 628.55k | 0.50% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 493.57k | 0.39% |
| HRT Financial LLCas of 31 Mar 2024 | 291.42k | 0.23% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
